⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of HepQuant, LLC and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
HepQuant, LLC
↗Aurora, Colorado, USA
HepQuant is a Denver-based, privately held diagnostics company focused on transforming the management of liver disease. The company develops non-invasive, blood-based, quantitative tests that measure critical liver cell processes and blood flow to provide a Disease Severity Index (DSI).
Their flagship technology, the HepQuant SHUNT® Liver Diagnostic Test, recently received FDA PMA approval. The company operates a CAP-accredited and CLIA-certified high-complexity laboratory to process its proprietary tests, which are used by healthcare providers to risk-stratify patients and inform clinical decisions regarding liver health.
CLASSIFICATION
Company Type:Diagnostics
Therapeutic Areas:-
Industry:Diagnostics
Sub-Industry:Liver Disease Diagnostics
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (FDA Approved)
Modalities:Diagnostic Device, Mass Spectrometry
Active Trials:1
Trial Phases:-
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Hepion Pharmaceuticals (Clinical collaboration for NASH trials)
COMPETITION
Position:Niche Player
Competitors:Echosens, Siemens Healthineers
LEADERSHIP
Key Executives:
Gregory T. Everson - CEO
Steve Helmke - Chief Scientific Officer
Joellyn Enos - Chief Commercial Officer
LINKS
Website:hepquant.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with HepQuant, LLC. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.